Letters (Westmoreland)

Letter to the editor: Prescription drug price reform top issue

Tribune-Review
By Tribune-Review
2 Min Read April 28, 2020 | 6 years Ago
Go Ad-Free today

While we all remain focused on stopping the spread of the coronavirus, it is important to remember that other health care challenges continue to negatively impact millions of Americans.

The challenge that I and many struggle with more and more is gaining access to the medications needed to treat multiple sclerosis. This is even more important to keep in mind now, considering the financial strain millions of Americans are experiencing — and will experience — as a result of the pandemic.

Unfortunately, since 2014, when I was diagnosed with MS, I have experienced several obstacles that have made it increasingly difficult for me to access the therapies I need. From the difficulty in getting the medication I and my health care provider know is best for me to the hoops I have had to jump through with my insurance provider just to get the medication and tests I need — sometimes the current system seems designed to make my health worse rather than better.

In considering candidates for president in the upcoming election, I’m looking for leadership and a commitment to finally do something to make prescription medications more accessible and affordable. This problem continues to get worse, not better, in my experience, and it’s time to put the needs of Pennsylvanians first. When I vote in the upcoming elections, the issue of prescription drug price reform will be my top priority.

Kristen O’Toole

Ross

Share

Tags:

About the Writers

Push Notifications

Get news alerts first, right in your browser.

Enable Notifications

Content you may have missed

Enjoy TribLIVE, Uninterrupted.

Support our journalism and get an ad-free experience on all your devices.

  • TribLIVE AdFree Monthly

    • Unlimited ad-free articles
    • Pay just $4.99 for your first month
  • TribLIVE AdFree Annually BEST VALUE

    • Unlimited ad-free articles
    • Billed annually, $49.99 for the first year
    • Save 50% on your first year
Get Ad-Free Access Now View other subscription options